Mirikizumab Shows Sustained Remission in Crohn's Disease and Ulcerative Colitis
Key Insights
Eli Lilly's mirikizumab demonstrates long-term efficacy in both ulcerative colitis (search) (UC) and Crohn's disease (search), marking it as the first IL-23p19 antagonist with multi-year sustained results.
LUCENT-3 study highlights that mirikizumab achieves histologic-endoscopic mucosal remission and provides sustained symptomatic, clinical, endoscopic, and histologic benefits in UC patients.
VIVID-2 long-term extension study reveals that mirikizumab maintains high rates of clinical and endoscopic remission in patients with moderately to severely active Crohn's disease (search).
Eli Lilly's mirikizumab has shown sustained, long-term remission in patients with both ulcerative colitis (search) (UC) and Crohn's disease (search), according to data presented at the American College of Gastroenterology (ACG) Annual Meeting. The Phase III clinical trials, LUCENT-3 and VIVID-2, highlight the potential of mirikizumab as a treatment for inflammatory bowel diseases (IBD).
Mirikizumab's Impact on Ulcerative Colitis
The LUCENT-3 study evaluated mirikizumab in patients with moderately to severely active UC. The results demonstrated that patients achieved long-term outcomes, including histologic-endoscopic mucosal remission. Furthermore, the study indicated sustained benefits across symptomatic, clinical, endoscopic, and histologic endpoints, suggesting a comprehensive improvement in disease management.
VIVID-2 Study Results in Crohn's Disease
The VIVID-2 long-term extension study assessed the efficacy of mirikizumab in patients with moderately to severely active Crohn's disease (search). The data revealed that patients maintained high rates of clinical and endoscopic remission, underscoring the drug's ability to provide lasting relief and intestinal healing.
Bruce Sands, MD, MS, from the Icahn School of Medicine at Mount Sinai, emphasized the importance of these findings, stating, "These multi-year data show mirikizumab is a targeted therapy that can provide intestinal healing over time and improvement in key symptoms that matter most to patients."
Guselkumab's Promising Data in Crohn's Disease
In related news, Johnson & Johnson shared new Phase III data from its GRAVITI trial of Tremfya (guselkumab). The results indicated that 56.1% of patients achieved clinical remission at 12 weeks, with remission rates continuing at 48 weeks with maintenance doses. According to J&J, Tremfya is the first and only IL-23 (search) inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease.
Remo Panaccione, MD, FRCPC, from the University of Calgary, noted, "The GRAVITI results show that induction treatment with subcutaneous guselkumab is as rapid and robust as we have seen with the IV induction, which could offer a welcome new option for Crohn’s disease treatment."